METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS WITH HUMAN MATRIX METALLOPROTEINASE AND A TNF ANTAGONIST

Title:

METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS WITH HUMAN MATRIX METALLOPROTEINASE AND A TNF ANTAGONIST

Document Type and Number:

WIPO Patent Application WO/2015/006469

Kind Code:

A3

Abstract:

The subject invention also provides a method of treating a subject afflicted with a fibroproliferative disorder comprising periodically administering to the patient an amount of one or more human matrix metalloproteinase, wherein the one or more human matrix metalloproteinase are selected from human metalloproteinase-1 (MMP-1), human metalloproteinase-2 (MMP- 2), human metalloproteinase-3 (MMP-3 ), human metalloproteinase-7 (MMP-7), human metalloproteinase-8 (MMP- 8), human metalloproteinase-9 (MMP-9 ), human metalloproteinase-10 (MMP-10 ), human metal loproteinase- 11 (MMP-11), metalloproteinase-12 (MMP-12), and human metalloproteinase-13 (MMP-13), and wherein the amount is effective to treat the subject. In an embodiment, the invention further comprises periodically administering to the subject an amount of TNF antagonist, wherein the amount of one or more the human matrix metalloproteinase and the amount of TNF antagonist when taken together are effective to treat the subject.

More Like This:

WO/2013/069701	WATER-DISPERSIBLE VAPORIZED ACTIVE SUBSTANCE SUSTAINED RELEASE PRODUCT
WO/2015/018624	INHIBITION OF BACTERIAL GROWTH IN PIPELINES
WO/1990/015138	RECOMBINANT RHIZOBIUM BACTERIA INOCULANTS

Inventors:

LARSEN GLENN (US)

Application Number:

PCT/US2014/045988

Publication Date:

November 05, 2015

Filing Date:

July 09, 2014

Export Citation:

Click for automatic bibliography generation Help

Assignee:

180 THERAPEUTICS LP (US)
LARSEN GLENN (US)

International Classes:

A01N63/00

Domestic Patent References:

WO2012056044A1

2012-05-03

Foreign References:

US20050186261A1

2005-08-25

Other References: